Roche's Genentech Announces New Results From Cll11 Study Show Gazyva Provided People With Previously Untreated Chronic Lymphocytic Leukemia A Treatment-Free Period Of Nearly Four Years at #ASH2015
December 05, 2015 at 10:31 AM EST
Genentech, a member of the Roche Group (OTC: RHHBY), announced today updated data from the pivotal CLL11 study confirming that Gazyva ...
